Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

Sorio Roberto; Roemer-Becuwe Celia; Hilpert Felix; Gibbs Emma; Garcia Yolanda; Kaern Janne; Huizing Manon; Witteveen Petronella; Zagouri Flora; Coeffic David; Luck Hans-Joachim; Gonzalez-Martin Antonio; Kristensen Gunnar; Levache Charles-Briac; Lee Chee Khoon; Gebski Val; Pujade-Lauraine Eric

首页> 外文期刊>Gynecologic Oncology: An International Journal >Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

【24h】

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

机译：含有单孕抗原患者的单孕贝伐单抗治疗的安全性和有效性抗性复发性卵巢癌：亚群分析III AURELIA试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. The AURELIA trial demonstrated significantly improved progression-free survival (PPS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC).

机译：背景。 Aurelia试验表明，在抗铂卵巢癌的化疗中添加了无进展的存活率（PPS）。

著录项

来源
《Gynecologic Oncology: An International Journal》 |2017年第1期|共7页
作者
Sorio Roberto; Roemer-Becuwe Celia; Hilpert Felix; Gibbs Emma; Garcia Yolanda; Kaern Janne; Huizing Manon; Witteveen Petronella; Zagouri Flora; Coeffic David; Luck Hans-Joachim; Gonzalez-Martin Antonio; Kristensen Gunnar; Levache Charles-Briac; Lee Chee Khoon; Gebski Val; Pujade-Lauraine Eric;
展开▼
作者单位

MITO Via F Gallini 2 I-33081 Aviano PN Italy;

GINECO 2 Rue Marie Marvingt F-54000 Nancy France;

AGO Moorkamp 2-6 D-20357 Hamburg Germany;

Univ Sydney Natl Hlth &

Med Res Council Clin Trials Ctr Sydney NSW 1450 Australia;

GEICO Parc Tauli 1 Barcelona 08208 Spain;

NSGO Postboks 4950 N-0424 Oslo Norway;

BGOG Wilrijkstr 10 B-2650 Edegem Belgium;

DGOG F02-126 POB 85500 NL-3508 GA Utrecht Netherlands;

HECOG 133 Vas Sofias Ave Athens 11528 Greece;

GINECO 38 Rue Courlancy F-51100 Reims France;

AGO Pelikanpl 23 D-30177 Hannover Germany;

GEICO C Arturo Soria 270 Madrid 28033 Spain;

NSGO Postboks 4950 N-0424 Oslo Norway;

GINECO 38 Blvd Vesone BP 4063 F-24000 Perigueux France;

Univ Sydney Natl Hlth &

Med Res Council Clin Trials Ctr Sydney NSW 1450 Australia;

Univ Sydney Natl Hlth &

Med Res Council Clin Trials Ctr Sydney NSW 1450 Australia;

GINECO 1 Pl Parvis Notre Dame Pl Jean Paul 2 F-75004 Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Elderly; Bevacizumab; Ovarian cancer; Platinum resistant; Patient-reported outcomes;

机译：老年人;Bevacizumab;卵巢癌;铂抗性;患者报告的结果;

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial [J] . Sorio Roberto, Roemer-Becuwe Celia, Hilpert Felix, Gynecologic Oncology: An International Journal . 2017,第1期

机译：含有单孕抗原患者的单孕贝伐单抗治疗的安全性和有效性抗性复发性卵巢癌：亚群分析III AURELIA试验
2. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial [J] . Poveda Andres M., Selle Frederic, Hilpert Felix, Journal of Clinical Oncology . 2015,第32期

机译：贝伐单抗联合每周紫杉醇，聚乙二醇化的脂质体阿霉素或托泊替康治疗铂类耐药性复发性卵巢癌：随机III期AURELIA试验的化学治疗队列分析
3. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial [J] . Eric Pujade-Lauraine, Felix Hilpert, Beatrice Weber, Obstetrical and gynecological survey . 2014,第7期

机译：贝伐单抗联合化学疗法治疗铂耐药的复发性卵巢癌：AURELIA公开标签随机III期试验
4. Analysis on the Efficacy and Safety of the Patients with Advanced Ovarian Cancer [C] . Yunxia Xue, Xingyun Sun, Peijing Shi International Forum on Bioinformatics and Medical Engineering . 2015

机译：晚期卵巢癌患者的疗效和安全性分析
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer [O] . Martin R. Stockler, Felix Hilpert, Michael Friedlander, -1

机译：公开报告的III期AURELIA试验评估含贝伐单抗的铂耐药性卵巢癌治疗的患者报告结果。
7. PCN176 Adding Bevacizumab To Single-Agent Chemotherapy For The Treatment Of Platinum-Resistant Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis Of The Aurelia Trial [O] . Schaffer EM, Coles TM, Wysham WZ, 2015

机译：PCN176将贝伐单抗添加到单剂化疗中以治疗铂类耐药的复发性卵巢癌：Aurelia试验的成本-效果分析

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

摘要

著录项

相似文献

相关主题

期刊订阅